PTH 1-34: Completed Phase IIa enrollment

Manhattan completed enrollment of 61 patients in a double-blind, placebo-controlled, U.S. Phase IIa trial evaluating two dose levels of topical PTH (1-34) applied twice daily for 8 weeks. The company ...